View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 19, 2021

NIH reports interferon is ineffective in hospitalised Covid-19 patients

Treatment with interferon beta-1a was linked to more adverse events in Covid-19 patients needing high-flow oxygen.

The National Institutes of Health (NIH) in the US has reported that interferon beta-1a in combination with remdesivir did not boost outcomes in an ACTT-3 clinical trial in hospitalised adult Covid-19 pneumonia patients.

A multiple sclerosis therapy, subcutaneous interferon beta-1a is produced and marketed by Merck KGaA, Darmstadt, Germany in the US while remdesivir is an antiviral manufactured by Gilead Sciences.

Sponsored and funded by NIH unit National Institute of Allergy and Infectious Diseases (NIAID), the trial recruited 969 subjects.

For enrolment, 63 sites were selected in the US, Mexico, Japan, South Korea and Singapore.

Subjects were randomised into a 1:1 ratio and given either interferon beta-1a plus remdesivir or placebo plus remdesivir.

The trial was carried out between 5 August and 21 December 2020.

Findings showed that interferon beta-1a in combination with remdesivir was not linked to clinical benefit versus remdesivir alone in hospitalised subjects with Covid-19.

Time to recovery was the primary outcome of the trial. Subjects treated with interferon beta-1a plus remdesivir, as well as those in the control arm had a median time to recovery of five days.

The chances of clinical improvement were also consistent across both trial arms at day 15.

The trial was amended on 4 September 2020 to suspend enrolment of severe Covid-19 patients who needed high-flow oxygen and exempt those who required non-invasive or invasive mechanical ventilation.

Modifications were made after the Data and Safety Monitoring Board (DSMB) of the trial found an increased frequency of severe adverse events in a subgroup of subjects needing high-flow oxygen on receiving interferon beta-1a.

The ACTT-3 trial investigators estimate that interferon could have amplified the inflammatory response, causing very severe respiratory disease in these subjects.

They added that the severe outcome could have arisen due to baseline imbalances between the interferon and control arms.

Remdesivir was used as an active control in the ACTT-3 trial as it demonstrated to be superior against placebo in reducing the time to recovery in hospitalised adult Covid-19 patients in the ACTT-1 trial.

This August, NIH commenced a trial to analyse a booster shot of an authorised or approved Covid-19 vaccine in autoimmune disease patients.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy